Platelet activation: a barrier to effective antitumor immunity

IF 5 3区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Cancer gene therapy Pub Date : 2025-05-27 DOI:10.1038/s41417-025-00915-7

Daolin Tang, Rui Kang

引用次数: 0

Abstract

Platelets, traditionally known for their role in hemostasis, are now recognized as key modulators of oncological processes, influencing tumor growth and metastasis through interactions with the tumor microenvironment. Recent studies reveal that platelet activation contributes to T-cell exhaustion by releasing thromboxane A2 (TXA2), which binds to the TBXA2R receptor and activates ARHGEF1, a guanine nucleotide exchange factor (GEF), leading to the suppression of T-cell function. This editorial explores the potential of repurposing anti-platelet drugs, such as aspirin, to counteract these effects. Aspirin, by inhibiting cyclooxygenase enzymes essential for TXA2 synthesis, can enhance T-cell activity in metastatic contexts, thereby improving immune surveillance and response. We advocate for further investigation into the thromboxane pathway’s impact on T-cell functionality and the development of aspirin-based therapeutic strategies to combat cancer metastasis.

Abstract Image

查看原文本刊更多论文

血小板活化：有效抗肿瘤免疫的屏障。

血小板，传统上以其止血作用而闻名，现在被认为是肿瘤过程的关键调节剂，通过与肿瘤微环境的相互作用影响肿瘤的生长和转移。最近的研究表明，血小板激活通过释放血栓素A2 （TXA2）促进t细胞衰竭，TXA2与TBXA2R受体结合，激活ARHGEF1，一种鸟嘌呤核苷酸交换因子（GEF），导致t细胞功能抑制。这篇社论探讨了重新利用抗血小板药物（如阿司匹林）来抵消这些影响的可能性。阿司匹林通过抑制TXA2合成所必需的环加氧酶，可以增强转移背景下t细胞的活性，从而改善免疫监测和反应。我们提倡进一步研究血栓素通路对t细胞功能的影响，并开发基于阿司匹林的治疗策略来对抗癌症转移。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer gene therapy 医学-生物工程与应用微生物

CiteScore

10.20

自引率

0.00%

发文量

150

审稿时长

4-8 weeks

期刊介绍： Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair. Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.